Published in Science on August 23, 1963
ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT. J Exp Med (1965) 15.47
BOUND COMPLEMENT AND IMMUNOLOGIC INJURY OF BLOOD VESSELS. J Exp Med (1965) 7.16
Formation and functional significance of a molecular complex derived from the second and the fourth component of human complement. J Exp Med (1967) 6.72
C'1 ESTERASE EFFECT ON ACTIVITY AND PHYSICOCHEMICAL PROPERTIES OF THE FOURTH COMPONENT OF COMPLEMENT. J Exp Med (1965) 4.23
ACTION OF COMPLEMENT IN HEREDITARY ANGIONEUROTIC EDEMA: THE ROLE OF C'1-ESTERASE. J Clin Invest (1964) 2.50
In vivo metabolism of complement. I. Metabolism of the third component (C'3) in acquired hemolytic anemia. J Clin Invest (1969) 1.26
Immune hemolysis: a simplified method for the preparation of EAC'4 with guinea pig or with human complement. J Immunol (1967) 8.06
Complement fixation on cell surfaces by 19S and 7S antibodies. Science (1965) 4.04
Hemolysin titration based on fixation of the activated first component of complement: evidence that one molecule of hemolysin suffices to sensitize an erythrocyte. J Immunol (1965) 3.42
BCG and cancer (first of two parts). N Engl J Med (1974) 2.13
Acquired cellular immunity: extracellular killing of Listeria monocytogenes by a product of immunologically activated macrophages. Cell Immunol (1974) 2.07
Suppression of tumor growth at the site of infection with living Bacillus Calmette-Guérin. J Natl Cancer Inst (1971) 2.04
Forssman antigen and antibody: preparation of water soluble antigen and measurement of antibody concentration by precipitin analysis, by C'1a fixation and by hemolytic activity. J Immunol (1966) 1.95
C'-1 fixation by human isoagglutinins: fixation of C'-1 by gamma-G and gamma-M but not by gamma-A antibody. J Immunol (1966) 1.80
Suppression of murine tumor growth by immune reaction to the Bacillus Calmette-Guérin strain of Mycobacterium bovis. J Natl Cancer Inst (1972) 1.75
BCG and cancer. N Engl J Med (1974) 1.66
Tumor immunity produced by the intradermal inoculation of living tumor cells and living Mycobacterium bovis (strain BCG). Science (1970) 1.64
Neutralization of sensitized virus by purified components of complement. Proc Natl Acad Sci U S A (1970) 1.63
Immune hemolysis and the functional properties of the second (C2) and fourth (C4) components of complement. 3. The hemolytic efficiency of human and guinea pig C2 and C4. J Immunol (1971) 1.60
Tumor regression after intralesional injection of emulsified trehalose-6,6'-dimycolate (cord factor): efficacy increases with oil concentration. Int J Cancer (1977) 1.56
Immunotherapy of cancer: regression of intradermal tumors and prevention of growth of lymph node metastases after intralesional injection of living Mycobacterium bovis. J Natl Cancer Inst (1972) 1.48
Histopathology of tumor regression after intralesional injection of Mycobacterium bovis. I. Tumor growth and metastasis. J Natl Cancer Inst (1972) 1.47
Tumor-specific antigen solubilized by hypertonic potassium chloride. J Natl Cancer Inst (1971) 1.46
Synthesis of the first component of human complement in vitro. J Exp Med (1968) 1.44
Production of the second (C2) and fourth (C4) components of guinea pig complement by single peritoneal cells: evidence that one cell may produce both components. J Immunol (1972) 1.44
Immunotherapy of cancer: regression of established intradermal tumors after intralesional injection of mycobacterial cell walls attached to oil droplets. J Natl Cancer Inst (1974) 1.42
Granuloma formation in lungs of mice after intravenous administration of emulsified trehalose-6,6'-dimycolate (cord factor): reaction intensity depends on size distribution of the oil droplets. Infect Immun (1977) 1.32
Tumor suppression by cell walls of mycobacterium bovis attached to oil droplets. J Natl Cancer Inst (1972) 1.32
In vitro synthesis of the first component of complement by guinea pig small intestine. Proc Natl Acad Sci U S A (1966) 1.30
A guinea pig model for tumor immunology. A summary. Isr J Med Sci (1973) 1.29
Antigenicity of a new diethylnitrosamine-induced transplantable guinea pig hepatoma: pathology and formation of ascites variant. J Natl Cancer Inst (1968) 1.28
Tumor-graft rejection in syngeneic guinea pigs: evidence for a two-step mechanism. J Natl Cancer Inst (1970) 1.27
Mouse complement: the effect of sex hormones and castration on two of the late-acting components. J Exp Med (1967) 1.26
Purification of the first component of complement by zonal ultracentrifugation. J Immunol (1969) 1.26
The C'la fixation and transfer test: examples of its applicability to the detection and enumeration of antigens and antibodies at cell surfaces. J Immunol (1968) 1.25
Neutralization of sensitized virus by the fourth component of complement. Science (1969) 1.21
Tumor regression mediated by Mycobacterium bovis (strain BCG). Effects of isonicotinic acid hydrazide, cortisone acetate, and antithymocyte serum. J Natl Cancer Inst (1973) 1.20
Synthesis of the first component of guinea pig complement by columnar epithelial cells of the small intestine. J Immunol (1968) 1.19
Synthesis of the second component of guinea pig complement in vitro. J Immunol (1971) 1.16
Immunotherapy of an intramuscular tumor in strain-2 guinea pigs: prevention of tumor growth by intradermal immunization and by systemic transfer of tumor immunity. J Natl Cancer Inst (1970) 1.14
Tumor-specific antigens detected by inhibition of macrophage migration. Science (1969) 1.13
Immunotherapy with an intralesionally administered synthetic cord factor analogue. Int J Cancer (1978) 1.11
125I protein A: applications to the quantitative determination of fluid phase and cell-bound IgG. J Immunol Methods (1977) 1.10
Studies on the terminal stages of immune hemolysis. VI. Osmotic blockers of differing Stokes' radii detect complement-induced transmembrane channels of differing size. J Immunol (1979) 1.09
Impaired inflammatory response in tumor-bearing guinea pigs. J Natl Cancer Inst (1972) 1.08
Influence of type of oil and surfactant concentration on the efficacy of emulsified Mycobacterium bovis BCG cell walls to induce tumor regression in guinea pigs. Infect Immun (1980) 1.07
Detection of bound C3 by a new immunochemical methods. J Immunol (1971) 1.06
Titration of the first component of complement on a molecular basis: suitability of IgM and unsuitability of IgG hemolysins as sensitizer. Immunochemistry (1969) 1.06
Toxicity of emulsified trehalose-6,6'-dimycolate (cord factor) in mice depends on size distribution of mineral oil droplets. Infect Immun (1978) 1.05
Influence of oil concentration on the efficacy of tumor regression by emulsified components of mycobacteria. Cancer Res (1979) 1.05
Development of an assay for aryl hydrocarbon (benzo(a)pyrene) hydroxylase in human peripheral blood monocytes. Cancer Res (1976) 1.05
Heterogeneity of rabbit IgM antibody as detected by C'1a fixation. J Exp Med (1968) 1.04
Failure of trehalose-6,6'-dimycolate (P3 or cord factor) to enhance endotoxin lethality in mice. Infect Immun (1976) 1.04
Studies on the terminal stages of immune hemolysis. III. Distinction between the insertion of C9 and the formation of a transmembrane channel. J Immunol (1978) 1.02
Brief communication: antigenic relationship between Mycobacterium bovis (BCG) and a guinea pig hepatoma. J Natl Cancer Inst (1973) 1.00
Antitumor activity of bacterial infection. I. Effect of Listeria monocytogenes on growth of a murine fibrosarcoma. J Natl Cancer Inst (1975) 0.99
Antitumor activity of bacterial infection. II. effect of Listeria monocytogenes on growth of a guinea pig hepatoma. J Natl Cancer Inst (1975) 0.99
Immunotherapy of cancer: an experimental model in syngeneic guinea pigs. Science (1970) 0.98
Efficiency of the first component of complement (C'1) in the hemolytic reaction. Science (1967) 0.98
Detection of antigens of a new diethylnitrosamine-induced transplantable hepatoma by delayed hypersensitivity. J Natl Cancer Inst (1968) 0.97
Immune hemolysis and the functional properties of the second (C2) and fourth (C4) components of complement. II. Clustering of effective C42 complexes at individual hemolytic sites. J Immunol (1971) 0.97
Isoelectric focusing of human and guinea-pig C2: polymorphism of guinea-pig C2. Immunology (1970) 0.97
Aryl hydrocarbon (benzo(a)pyrene) hydroxylase in human peripheral blood monocytes. Nature (1974) 0.96
Transplantable hepatomas induced in strain-2 guinea pigs by diethylnitrosamine: characterization by histology, growth, and chromosomes. J Natl Cancer Inst (1969) 0.96
Histopathology of tumor regression after intralesional injection of Mycobacterium bovis. IV. Development of immunity to tumor cells and BCG. J Natl Cancer Inst (1973) 0.96
Correlation between the ability of tumor cells to resist humoral immune attack and their ability to synthesize lipid. J Immunol (1978) 0.96
Studies on the terminal stages of immune hemolysis. V. Evidence that not all complement-produced transmembrane channels are equal. J Immunol (1979) 0.96
Studies on the interaction between protein A and immunoglobulin G. II. Composition and activity of complexes formed between protein A and IgG. J Immunol (1978) 0.96
Cold-reacting antibodies: the enhancement of antibody fixation by the first component of complement (C'1a). J Immunol (1968) 0.96
Mouse complement: influence of sex hormones on its activity. Science (1966) 0.96
Immune hemolysis and the functional properties of the second (C2) and fourth (C4) components of complement. I. Functional differences among C4 sites on cell surfaces. J Immunol (1970) 0.95
Intralesional immunotherapy of melanoma with BCG. Med Clin North Am (1976) 0.95
Histopathology of tumor regression after intralesional injection of Mycobacterium bovis., 2. Comparative effects of vaccinia virus, oxazolone, and turpentine. J Natl Cancer Inst (1972) 0.95